Project Grant R01AI169457
- Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $130,564 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of Pittsburgh, effective July 1, 2026 through June 30, 2027. This research grant funds investigative work on the host determinants of Enterovirus D68 (EV-D68) immunity and neuropathogenesis. The project examines the mechanisms by which EV-D68 causes poliomyelitis-like illness characterized...
- Grant Award Summary Children's Mercy Hospital received a $433,175 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective July 1, 2025 through June 30, 2027. The award supports the development of a mosaic messenger ribonucleic acid (mRNA) vaccine designed to prevent hand, foot, and mouth disease (HFMD) caused by human enterovirus A viruses. The research deliverables include the design...
- The National Science Foundation (NSF) awarded a $802,161 Project Grant to the University of Massachusetts Medical School (UMass Medical) to study the structural mechanisms of bacteriophage (phage) infection and assembly. This 3-year grant, effective June 1, 2024, aims to advance the understanding of virus-host interactions, promote the development of effective antiviral strategies, and leverage phage-related applications. The research will focus on three aspects of the phage life cycle: virus...
- Grant Award Summary Pennsylvania State University's Penn State Milton S. Hershey Medical Center received a Project Grant of $222,457 from the National Institute of Allergy and Infectious Diseases under the Allergy and Infectious Diseases Research program (CFDA 93.855) for the period June 3, 2026 through May 31, 2028. The award supports research to characterize structural polymorphism in native murine polyomavirus (MPYV) particles isolated directly from infected mouse cells. Using an integrated...
- This Project Grant award from the National Science Foundation (NSF) under the Biological Sciences (CFDA 47.074) Federal Grant Program provides $987,566 to the University of California, Los Angeles (UCLA) to conduct research on viral self-assembly, from test tube to cell cytoplasm. The award period runs from December 15, 2024 to November 30, 2028. The key objectives of this project are to elucidate the differences between in vitro and in cellulo viral processes by progressively adding molecules...
- Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded a Project Grant of $190,315 to the University of Colorado-Denver under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective September 1, 2025, through August 31, 2030. This research initiative will investigate immunologic predictive factors of Enterovirus D68 (EV-D68) disease presentations in acutely exposed and infected individuals. The project will analyze previously and...
- Federal Grant Award Summary The University of Pittsburgh has received a $430,170 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), with an award date of July 9, 2025 and completion deadline of June 30, 2027. This project will deliver research services focused on identifying viral genetic determinants of Enterovirus D68 (EV-D68) neuropathogenesis using an innovative human spinal cord...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $360,000 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Virginia Polytechnic Institute & State University (Virginia Tech) to develop a gerbil model to delineate the mechanism of Hepatitis E Virus (HEV) extrahepatic pathogenesis. The key objectives are to: 1) Determine the effect of HEV-3-induced pyroptosis in neurovascular unit (NVU) cells and identify the mechanisms of...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded The Leland Stanford Junior University a $3,045,291 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) effective August 1, 2025 through July 31, 2029. This collaborative research initiative, led by the Carette, Chiu, and Nagamine laboratories, will investigate the molecular mechanisms by which the MFSD6 (Major Facilitator Superfamily Domain-containing 6)...
- Federal Project Grant Summary The University of Pittsburgh received a $416,873 Project Grant award dated June 18, 2026, from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award, which concludes May 31, 2028, funds research on EV-D68 (Enterovirus D68) and immune modulation mechanisms in human spinal cord organoids (HSCOs). The research addresses the neuropathogenesis of acute flaccid myelitis...
UNDERSTANDING THE FUNDAMENTAL ENTEROVIRUS CAPSID ASSEMBLY AND MATURATION PATHWAY. - PROJECT SUMMARY/ABSTRACT: ENTEROVIRUSES (EVS) COMPRISE A FAMILY OF POSITIVE SENSE SSRNA VIRUSES. THE MOST WELL-STUDIED IS POLIOVIRUS, YET NON-POLIO ENTEROVIRUSES (NPEVS) CAUSE SERIOUS DISEASE, ESPECIALLY IN THE VERY YOUNG. THIS INCLUDES HAND, FOOT AND MOUTH DISEASE, FLACCID MYELITIS AND ENCEPHALITIS. CURRENTLY, IT IS ESTIMATED THAT NPEVS ARE RESPONSIBLE FOR OVER 10 MILLION INFECTIONS AND TENS OF THOUSANDS OF HOSPITALIZATIONS IN THE US ALONE. FURTHERMORE, COINFECTIONS ARE COMMON AND THEREFORE IT IS LIKELY THAT NEW VIRUSES WILL ARISE AS A RESULT OF RECOMBINATION. UNDERSTANDING KEY EVENTS THAT ARE SHARED ACROSS NPEVS IS THEREFORE KEY TO BEING ABLE TO CONTROL CURRENT INFECTIONS AND RESPOND TO EMERGING DISEASE IN THE FUTURE. ONE OF THESE KEY EVENTS IS POLYPROTEIN PROCESSING. THE NPEV GENOME ENCODES A POLYPROTEIN WHICH IS PROTEOLYTICALLY CLEAVED INTO THE MATURE VIRAL PROTEINS REQUIRED FOR THE GENERATION OF PROGENY VIRUS. THE STRUCTURAL REGION OF THE POLYPROTEIN IS PROCESSED INTO VP0, VP3 AND VP1. THESE ASSEMBLE INTO A PROTOMER, FIVE OF WHICH ASSEMBLE INTO A PENTAMER. TWELVE PENTAMERS COALESCE AROUND THE VIRAL GENOME, GENERATING A STRUCTURE TERMED THE PROVIRION. THE ASSEMBLY OF THE PROVIRION INDUCES A SERIES OF CONFORMATIONAL CHANGES WHICH RESULT IN THE CLEAVAGE OF VP0 INTO VP4 AND VP2. THIS OCCURS RAPIDLY UPON GENOME ENCAPSIDATION, THUS THE PROVIRION IS SHORT-LIVED AND POORLY CHARACTERIZED. THE CLEAVAGE OF VP0 INTO VP4 AND VP2 OCCURS WITHIN THE ASSEMBLED PARTICLE IN AN RNA-DEPENDENT MANNER AND IS A PREREQUISITE FOR EV INFECTIVITY. UNDERSTANDING THE PROVIRION AND CHARACTERISING THE KEY CONFORMATIONAL CHANGES WHICH PRECEDE VP0 CLEAVAGE IS THE FOCUS OF THIS APPLICATION. WE PROPOSE THAT THE MECHANISM OF VP0 MATURATION CLEAVAGE IS CONSERVED ACROSS ALL EVS, AND THAT UNDERSTANDING THIS PROCESS WILL INFORM THE DEVELOPMENT OF FUTURE VACCINES AND ANTI-VIRAL THERAPIES. THE CURRENT MODEL OF VP0 CLEAVAGE AND EV MATURATION IS HEAVILY BASED ON DATA FROM POLIOVIRUS (PV), AND SUGGEST A CATALYTIC ROLE FOR RNA IN VP0 MATURATION. HOWEVER, WE HYPOTHESISE THAT GENOME PACKAGING INITIATES CONFORMATIONAL CHANGES WHICH FACILITATE THE FORMATION OF A PROTEINACEOUS CATALYTIC POCKET. WE SUGGEST THAT IDENTIFYING ALLOSTERIC AND CATALYTIC CHANGES WHICH STABILIZE PROVIRIONS WILL ALLOW US TO CAPTURE THE MOLECULAR DETAILS OF THE CATALYTIC SITE AT ATOMIC RESOLUTION. USING A SERIES OF COMPLEMENTARY TECHNIQUES AND A REITERATIVE APPROACH, WE PROPOSE TO TRAP ASSEMBLY INTERMEDIATES AND CHARACTERIZE THE CRITICAL RESIDUES AND CONFORMATIONAL CHANGES THAT MEDIATE VP0 CLEAVAGE WITHIN THE ASSEMBLED VIRUS PARTICLE. WE WILL INITIALLY USE EVA71 AS OUR PROTOTYPE NPEV AND PAN-EV PHENOTYPES WILL BE CONFIRMED BY VERIFYING FINDINGS IN ECHOVIRUS 7, POLIOVIRUS, AND EVD68. OUR PRELIMINARY DATA DEMONSTRATE THE FEASIBILITY OF GENERATING MUTATIONALLY-STABILIZED PROVIRIONS WITH YIELDS SUITABLE FOR STRUCTURAL STUDIES. ADDITIONAL DATA SUPPORT THE TRACTABILITY OF DEVELOPING INHIBITORS OF CAPSID ASSEMBLY. BY THESE APPROACHES WE WILL DEFINE THE CONSERVED MECHANISM OF VP0 CLEAVAGE WHICH WILL BE APPLICABLE TO TREATING BOTH CURRENT NPEV INFECTIONS AND THOSE YET TO ARISE.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $573.7k | 2/26/26 | ||
| Not listed | $522.9k | 2/13/25 | ||
| Not listed | $46.0k | 4/15/24 | ||
| Not listed | $46.0k | 4/15/24 | ||
| Not listed | $391.0k | 2/27/24 |